ATG as disease-modifying therapy for new-onset type 1 diabetes. Speake C. Lancet 2025 Sep 18:S0140-6736(25)01773-8. doi: 10.1016/S0140-6736(25)01773.

Read + Share

Amedeo Smart

Independent Medical Education

Speake C. ATG as disease-modifying therapy for new-onset type 1 diabetes. Lancet 2025 Sep 18:S0140-6736(25)01773-8. doi: 10.1016/S0140-6736(25)01773.
PMID: 40976250